Drug Trial Radar · NCT05278338
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
Last checked: Nov 19, 2026Latest source record: Jul 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 21, 2022
Primary completion
Dec 31, 2023
Study completion Mar 31, 2024
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.
Conditions
- Postmenopausal Osteoporosis
Interventions
JMT103Drug
subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
DenosumabDrug
subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
PlaceboDrug
subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change rate of lumbar bone mineral density (BMD) from baseline at 12 months of JMT103 treatmentTime frame: Baseline and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.